Exchange: NYSE·Updated 07:49 PM EDT
MRK logo

MRKMerck & Co Inc

$125.37
$3.13
(2.44%)
Today
Closed $125.37
$0.39
(0.31%)
After Hours
EarningsAug 4
Mkt Cap$317.37B
Vol10.76M
News
all
press releases
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership
Merck cited business reasons for the discontinuation of the investigational drug.
Stocktwits
News Placeholder
More News
News Placeholder
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Aug. 4. During the call, company executives will provide an overview of Mercks...
Business Wire
News Placeholder
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.
Zacks
News Placeholder
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks
News Placeholder
Lilly (LLY) Moves 7.1% Higher: Will This Strength Last?
Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced an agreement with the ADAP Crisis Task Force (ACTF) to help state AIDS Drug Assistance Programs (ADAPs) provide access to the companys new once-daily HIV treatment, IDVYNSO (doravirine/islatravir). In 2024...
Business Wire
News Placeholder
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session.
Zacks
News Placeholder
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Zacks
News Placeholder
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
Zacks
News Placeholder
MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer
Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Zacks
<
1
2
...
>

Advertisement|Remove ads.